Omid Hamid, MD, and Ryan Sullivan, MD, discuss new updates in uveal melanoma, and an exciting, recently approved agent for treatment of metastatic disease.
EP. 1: Overview of Metastatic Uveal Melanoma
Ryan Sullivan, MD, provides an overview of metastatic uveal melanoma, currently available treatment options, and unmet needs in the field.
EP. 2: Novel Immunotherapy Agent Tebentafusp for Treatment of Metastatic Uveal Melanoma
Dr Omid Hamid explains the mechanism of action of recently approved tebentafusp for mUM, and why HLA testing is necessary for patients being considered for the treatment.
EP. 3: Recent Trial Data on Tebentafusp in Metastatic Uveal Melanoma
Dr Ryan Sullivan details clinical trial data presented at ASCO 2022 on the use of tebentafusp for mUM.
EP. 4: Managing Tebentafusp Toxicities in Metastatic Uveal Melanoma
Experts highlight strategies for managing the adverse events of tebentafusp, especially cytokine release syndrome.
EP. 5: Future Directions in Metastatic Uveal Melanoma Treatment
Omid Hamid, MD, and Ryan Sullivan, MD, discuss what they look forward to in the future of metastatic uveal melanoma treatment.
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC